rabbit anti tap1  (Proteintech)

Journal: International Journal of Molecular Sciences

Article Title: Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target

doi: 10.3390/ijms252111853

Figure Lengend Snippet: Western blotting of benign cell lines confirmed the variable expression of a 72 kDa ENOX2 isoform in keratinocytes (FKs), fibroblasts (FF1, FF2) and melanocytes (FM1, FM2). The melanoma cell line A-375 is shown for comparison. The same ENOX2 isoform that was expressed in benign cell lines was also mainly present in melanoma cell lines (see ). The experimental samples using ENOX2 and β -actin were run on the same blot/gel. S = sensitive to vemurafenib, R = resistant to vemurafenib.

Article Snippet: Proteins were detected with primary antibodies against ENOX2 (Proteintech Group, Rosemont, IL, USA, #10423-1-AP, diluted 1:1000), Cell Signaling Technology (Danvers, MA, USA) antibodies against phospho-AKT (Ser473, #4060, diluted 1:2000), AKT (#9272, diluted 1:1000), phospho-ERK (Thr202/Tyr204, #4376, diluted 1:1000), ERK (#9102, diluted 1:1000) and β -actin (#4967, #3700, diluted 1:1000), as well as secondary antibodies coupled to horseradish peroxidase (Cell Signaling Technology, Danvers, MA, USA, diluted 1:1000) with Pierce ECL Western Blotting and SuperSignal West Dura Extended Duration Substrate (Thermo Fisher, Waltham, MA, USA) using the Amersham Imager 600 (GE Healthcare, Chicago, IL, USA).

Techniques: Western Blot, Expressing, Comparison

Journal: International Journal of Molecular Sciences

Article Title: Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target

doi: 10.3390/ijms252111853

Figure Lengend Snippet: Exemplary Western blot of BRAFi-sensitive (S) and -resistant (R) melanoma cell line A-375 under therapy with 2 μ M vemurafenib, 5 μ M PXD, combination of both or control treatment. The sensitive cell line shows an upregulation of phospho-AKT under BRAFis, which can be attenuated by administration of PXD. The experimental samples using ENOX2 and β -Actin, pAKT and ERK, as well as pERK and AKT, were each run on the same blot/gel. Additional results are presented in .

Article Snippet: Proteins were detected with primary antibodies against ENOX2 (Proteintech Group, Rosemont, IL, USA, #10423-1-AP, diluted 1:1000), Cell Signaling Technology (Danvers, MA, USA) antibodies against phospho-AKT (Ser473, #4060, diluted 1:2000), AKT (#9272, diluted 1:1000), phospho-ERK (Thr202/Tyr204, #4376, diluted 1:1000), ERK (#9102, diluted 1:1000) and β -actin (#4967, #3700, diluted 1:1000), as well as secondary antibodies coupled to horseradish peroxidase (Cell Signaling Technology, Danvers, MA, USA, diluted 1:1000) with Pierce ECL Western Blotting and SuperSignal West Dura Extended Duration Substrate (Thermo Fisher, Waltham, MA, USA) using the Amersham Imager 600 (GE Healthcare, Chicago, IL, USA).

Techniques: Western Blot, Control

Journal: International Journal of Molecular Sciences

Article Title: Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target

doi: 10.3390/ijms252111853

Figure Lengend Snippet: Additional western blots and replicas of melanoma cell lines under therapy with 2 μ M vemurafenib, 5 μ M PXD, combination of both or control treatment. The experimental samples using ENOX2 and β -Actin, pAKT and ERK as well as pERK and AKT were each run on the same blot/gel.

Article Snippet: Proteins were detected with primary antibodies against ENOX2 (Proteintech Group, Rosemont, IL, USA, #10423-1-AP, diluted 1:1000), Cell Signaling Technology (Danvers, MA, USA) antibodies against phospho-AKT (Ser473, #4060, diluted 1:2000), AKT (#9272, diluted 1:1000), phospho-ERK (Thr202/Tyr204, #4376, diluted 1:1000), ERK (#9102, diluted 1:1000) and β -actin (#4967, #3700, diluted 1:1000), as well as secondary antibodies coupled to horseradish peroxidase (Cell Signaling Technology, Danvers, MA, USA, diluted 1:1000) with Pierce ECL Western Blotting and SuperSignal West Dura Extended Duration Substrate (Thermo Fisher, Waltham, MA, USA) using the Amersham Imager 600 (GE Healthcare, Chicago, IL, USA).

Techniques: Western Blot, Control